{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T08:09:09Z","timestamp":1780992549858,"version":"3.54.1"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","drugandalcoholdependence.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1016\/j.drugalcdep.2015.04.007","type":"journal-article","created":{"date-parts":[[2015,4,21]],"date-time":"2015-04-21T14:16:30Z","timestamp":1429625790000},"page":"164-169","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Buprenorphine\/naloxone treatment practices in Malaysia: Results of national surveys of physicians and patients"],"prefix":"10.1016","volume":"152","author":[{"given":"B.","family":"Vicknasingam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.N.M.","family":"Dazali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.S.","family":"Schottenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.C.","family":"Chawarski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugalcdep.2015.04.007_bib0005","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1080\/00952990802122259","article-title":"Case series of buprenorphine injectors in Kuala Lumpur, Malaysia","volume":"34","author":"Bruce","year":"2008","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"10.1016\/j.drugalcdep.2015.04.007_bib0010","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1080\/00952990802585406","article-title":"Lack of reduction in buprenorphine injection after introduction of co-formulated buprenorphine\/naloxone to the Malaysian market","volume":"35","author":"Bruce","year":"2009","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"10.1016\/j.drugalcdep.2015.04.007_bib1015","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.drugalcdep.2011.12.024","article-title":"Lifetime ATS use and increased HIV risk among not-in-treatment opiate injectors in Malaysia","volume":"124","author":"Chawarski","year":"2012","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2015.04.007_bib0025","first-page":"492","article-title":"Abuse and prescription buprenorphine regulatory controls","volume":"35","author":"Chua","year":"2006","journal-title":"Ann. Acad. Med."},{"key":"10.1016\/j.drugalcdep.2015.04.007_bib0015","first-page":"1","article-title":"Use and misuse of buprenorphine in the management of opioid addiction","volume":"3","author":"Cicero","year":"2007","journal-title":"J. Opioid Manage."},{"key":"10.1016\/j.drugalcdep.2015.04.007_bib0020","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.drugalcdep.2014.06.005","article-title":"Factors contributing to the rise of buprenorphine misuse 2008\u20132013","volume":"142","author":"Cicero","year":"2014","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2015.04.007_bib0030","series-title":"Global AIDS Response Country Progress Report Malaysia 2012","author":"Global AIDS Response","year":"2012"},{"key":"10.1016\/j.drugalcdep.2015.04.007_bib0035","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1159\/000104883","article-title":"Buprenorphine misuse among heroin and amphetamine users in Malmo, Sweden: purpose of misuse and route of administration","volume":"13","author":"Hakansson","year":"2007","journal-title":"Eur. Addict. Res."},{"key":"10.1016\/j.drugalcdep.2015.04.007_bib0040","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.neubiorev.2012.11.012","article-title":"From Kratom to mitragynine and its derivatives: physiological and behavioural effects related to use, abuse, and addiction","volume":"37","author":"Hassan","year":"2013","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.drugalcdep.2015.04.007_bib0045","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1360-0443.2004.00958.x","article-title":"Buprenorphine diversion and injection in Melbourne, Australia: an emerging issue?","volume":"100","author":"Jenkinson","year":"2005","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2015.04.007_bib0050","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/QAI.0b013e3181bbc9af","article-title":"Impact of HIV preventionprogramson drug users in Malaysia","volume":"52","author":"Kamarulzaman","year":"2009","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.drugalcdep.2015.04.007_bib0055","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.drugalcdep.2013.12.005","article-title":"The diversion and injection of buprenorphine\u2013naloxone soluble film formulation","volume":"136","author":"Larance","year":"2014","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2015.04.007_bib0060","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jsat.2014.02.003","article-title":"Abuse and diversion of buprenorphine sublingual tablets and film","volume":"47","author":"Lavonas","year":"2014","journal-title":"J. Subst. Abuse Treat."},{"key":"10.1016\/j.drugalcdep.2015.04.007_bib0065","first-page":"919","article-title":"Tackling subutex abuse in Singapore","volume":"47","author":"Lee","year":"2006","journal-title":"Singapore Med. J."},{"key":"10.1016\/j.drugalcdep.2015.04.007_bib0070","doi-asserted-by":"crossref","first-page":"345","DOI":"10.2217\/pmt.12.26","article-title":"Buprenorphine for opioid addiction","volume":"2","author":"Ling","year":"2012","journal-title":"Pain Manage."},{"issue":"2","key":"10.1016\/j.drugalcdep.2015.04.007_bib0075","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002207.pub4","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","author":"Mattick","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.drugalcdep.2015.04.007_bib0080","series-title":"Paper Presented at the WHO Workshop on Drug Abuse and HIV AIDS","article-title":"Current trends of drug abuse in Malaysia: its implications for the HIV problems","author":"Nazar","year":"2007"},{"key":"10.1016\/j.drugalcdep.2015.04.007_bib0085","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/j.1360-0443.2006.01731.x","article-title":"Concurrent buprenorphine and benzodiazepine use and self-reported opioid toxicity substitution","volume":"102","author":"Nielsen","year":"2007","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2015.04.007_bib0090","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1046\/j.1360-0443.2001.96226710.x","article-title":"Injecting misuse of buprenorphine among French drug users","volume":"96","author":"Obadia","year":"2001","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2015.04.007_bib0095","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/0006-3223(93)90258-F","article-title":"Buprenorphine: dose-related effects on cocaine and opioid use in cocaine-abusing opioid dependent humans","volume":"34","author":"Schottenfeld","year":"1993","journal-title":"Biol. Psychiatty"},{"key":"10.1016\/j.drugalcdep.2015.04.007_bib0100","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1001\/archpsyc.1997.01830200041006","article-title":"Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse","volume":"54","author":"Schottenfeld","year":"1997","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2015.04.007_bib0105","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jfda.2013.09.033","article-title":"Substance abuse and HIV situation in Malaysia","volume":"21","author":"Singh","year":"2013","journal-title":"J. Food Drug Anal."},{"key":"10.1016\/j.drugalcdep.2015.04.007_bib0110","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1600-0447.1992.tb03224.x","article-title":"Cases of buprenorphine abuse in India","volume":"86","author":"Singh","year":"1992","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.drugalcdep.2015.04.007_bib0115","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/S0140-6736(85)92961-7","article-title":"Abuse of buprenorphine","volume":"28","author":"Strang","year":"1985","journal-title":"Lancet"},{"key":"10.1016\/j.drugalcdep.2015.04.007_bib0120","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1080\/09540120802657530","article-title":"The relative risk of HIV infection among IDUs not in treatment in Malaysia","volume":"21","author":"Vicknasingam","year":"2009","journal-title":"AIDS Care"},{"key":"10.1016\/j.drugalcdep.2015.04.007_bib0125","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.drugalcdep.2010.03.014","article-title":"Injection of buprenorphine and buprenorphine\/naloxone tablets in Malaysia","volume":"111","author":"Vicknasingam","year":"2010","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2015.04.007_bib0130","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0376-8716(02)00312-5","article-title":"Intravenous use of prescribed sublingual buprenorphine tablets by drug users receiving maintenance therapy in France","volume":"69","author":"Vidal-Trecan","year":"2003","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2015.04.007_bib0135","doi-asserted-by":"crossref","first-page":"28","DOI":"10.2174\/1874473711104010028","article-title":"Buprenorphine and buprenorphine\/naloxone diversion, misuse, and illicit use: an international review","volume":"1","author":"Yokell","year":"2011","journal-title":"Curr. Drug Abuse Rev."}],"container-title":["Drug and Alcohol Dependence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871615002021?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871615002021?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,23]],"date-time":"2018-09-23T04:53:04Z","timestamp":1537678384000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0376871615002021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":28,"alternative-id":["S0376871615002021"],"URL":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2015.04.007","relation":{},"ISSN":["0376-8716"],"issn-type":[{"value":"0376-8716","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Buprenorphine\/naloxone treatment practices in Malaysia: Results of national surveys of physicians and patients","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2015.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}